Halozyme is a therapeutically driven biopharmaceutical company developing and commercializing recombinant human enzymes to provide enhanced and innovative products that improve the practice of medicine. Halozyme focuses on providing life-saving and life-enhancing solutions to the diabetes, oncology, dermatology, and drug delivery markets.
The foundation of our capabilities is our recombinant human hyaluronidase enzyme, rHuPH20, which temporarily degrades hyaluronan, a structural protein in the interstitial space. This temporary alteration provides an opportunistic window that allows the delivery of injectable biologics such as monoclonal antibodies, as well as small molecules and fluids. With our enzyme, pharmaceuticals that would normally be injected intravenously (IV) might be administered subcutaneously (SC). This change in route of delivery might also improve patient convenience, enhance pharmacokinetics, boost efficacy, extend the product lifecycle, and reduce cost, in addition to other beneficial attributes.
Our proprietary product development portfolio consists of HYLENEX® recombinant, an FDA-approved hyaluronidase human injection in 150 USP Units/mL single dose vial plus three product development programs. The diabetes program consists of Insulin-PH20 and Analog-PH20, which is evaluating use of our rHuPH20 enzyme currently approved and marketed mealtime insulin products. The oncology franchise consists of PEGPH20, an investigational new molecular entity administered intravenously that targets the external environment of solid tumor cells. Our lead enzyme within dermatology is HTI-501, a molecule which degrades collagen. It may have applications in both medical and aesthetic dermatology and other potential therapeutic categories as well.
Our product development pipeline also includes partnered programs with Roche, Pfizer, Janssen, Baxter and AbbVie. These partnered programs validate our technology and may generate clinical and commercial milestone revenue based on the achievement of pre-specified events along with sales royalties when products reach the commercial stage. We utilize the non-dilutive cash milestone payments generated from the partnered programs as a source of development funding for our proprietary pipeline projects.